OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

May 31, 2026

Conditions
SepsisCommunity Acquired Pneumonia (CAP)
Interventions
DRUG

OPT101

OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

OTHER

Placebo

0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.

Trial Locations (1)

80204

Denver Health and Hospital Authority, Denver

All Listed Sponsors
lead

Op-T LLC

INDUSTRY